Wir verwenden Cookies, um ihnen eine bessere Recherche zu bieten, um Website-Aktivitäten zu analysieren und Inhalte zu personalisieren. Bitte lesen Sie diese Cookie-Richtlinie sorgfältig durch. Indem Sie diese Webseite weiterhin benutzen, stimmen Sie dieser Cookie-Richtlinie sowie zusätzlich sämtliche anderen geltenden Geschäftsbedingungen, einschließlich der Datenschutzrichtlinie und der Nutzungsbedingungen, zu.

ICH STIMME ZU

Suchfilter

Neuigkeiten

Bleiben Sie auf dem neuesten Stand. Hier finden Sie unsere Pressemitteilungen. Hier können Sie sich über bevorstehende Veranstaltungen informieren, an denen Curium teilnehmen wird.

8th September 2020

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

9th Juni 2020

Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe

16th April 2020

Eine Erklärung von Curium zu COVID-19 und unseren Maßnahmen

24th März 2020

Curium Announces Approval of Pulmotech^TM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration

12th März 2020

RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA

3rd März 2020

Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio

30th Januar 2020

Curium is attending these global congresses in 2020

7th Januar 2020

RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application

2nd Dezember 2019

Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy

16th November 2019

CEO Today Healthcare Awards Winner 2019

13th November 2019

Curium Announces Plan to Submit an Application to Market Generic Ioflupane I 123 Injection in the U.S.

19th September 2019

Kooperation von Curium und ROTOP zur Versorgung von Patienten mit STRIASCAN^TM

4th September 2019

Curium Announces Revised Pricing for Technescan MAG3^TM (kit for the preparation of technetium Tc 99m mertiatide)

22nd Februar 2019

Curium is attending these global congresses in 2019

13th Februar 2019

Campaign to Support FDA Approved Products

5th Februar 2019

Curium Petten and NRG Agreement

27th August 2018

Curium und RadioMedix geben eine exklusive Vereinbarung für die ⁶⁴Cu-Dotatate-Entwicklung bekannt.

10th Mai 2018

Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas

2nd Mai 2018

Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations

11th April 2018

FILTERN NACH

Neuigkeiten

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe

Eine Erklärung von Curium zu COVID-19 und unseren Maßnahmen

Curium Announces Approval of Pulmotech^TM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration

RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA

Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio

Curium is attending these global congresses in 2020

RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application

Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy

CEO Today Healthcare Awards Winner 2019

Curium Announces Plan to Submit an Application to Market Generic Ioflupane I 123 Injection in the U.S.

Kooperation von Curium und ROTOP zur Versorgung von Patienten mit STRIASCAN^TM

Curium Announces Revised Pricing for Technescan MAG3^TM (kit for the preparation of technetium Tc 99m mertiatide)

Curium is attending these global congresses in 2019

Campaign to Support FDA Approved Products

Curium Petten and NRG Agreement

Curium und RadioMedix geben eine exklusive Vereinbarung für die ⁶⁴Cu-Dotatate-Entwicklung bekannt.

Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas

Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations

Curium übernimmt die französischen Vertriebs – und Produktionsakivitäten von Cyclopharma

FILTERN NACH

Neuigkeiten

RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.

Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe

Eine Erklärung von Curium zu COVID-19 und unseren Maßnahmen

Curium Announces Approval of PulmotechTM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration

RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA

Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio

Curium is attending these global congresses in 2020

RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application

Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy

CEO Today Healthcare Awards Winner 2019

Curium Announces Plan to Submit an Application to Market Generic Ioflupane I 123 Injection in the U.S.

Kooperation von Curium und ROTOP zur Versorgung von Patienten mit STRIASCANTM

Curium Announces Revised Pricing for Technescan MAG3TM (kit for the preparation of technetium Tc 99m mertiatide)

Curium is attending these global congresses in 2019

Campaign to Support FDA Approved Products

Curium Petten and NRG Agreement

Curium und RadioMedix geben eine exklusive Vereinbarung für die 64Cu-Dotatate-Entwicklung bekannt.

Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas

Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations

Curium übernimmt die französischen Vertriebs – und Produktionsakivitäten von Cyclopharma

Curium Announces Approval of Pulmotech^TM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration

Kooperation von Curium und ROTOP zur Versorgung von Patienten mit STRIASCAN^TM

Curium Announces Revised Pricing for Technescan MAG3^TM (kit for the preparation of technetium Tc 99m mertiatide)

Curium und RadioMedix geben eine exklusive Vereinbarung für die ⁶⁴Cu-Dotatate-Entwicklung bekannt.